Table 3.
Estimated Patient Costs Across Time, Risk Group, and Event Statusa
| Risk Group | Year | No Bladder Cancer | NMIBC Recurrence |
MIBC Progression | ||
|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | ||||
| High | ||||||
| 1 | £4796 | £6014 | £6472 | £8753 | £10,374 | |
| 2 | £2363 | £3581 | £4039 | £6320 | £7940 | |
| 3 | £1387 | £2605 | £3063 | £5344 | £6964 | |
| Intermediate | ||||||
| 1 | £2828 | £4046 | £4505 | £6785 | £8406 | |
| 2 | £1907 | £3125 | £3583 | £5864 | £7484 | |
| 3 | £1314 | £2532 | £2990 | £5271 | £6891 | |
Abbreviations: HRQoL = health-related quality of life; MIBC = muscle-invasive bladder cancer; NA = not applicable; NMIBC = non–muscle-invasive bladder cancer.
a
Predicted values from a multivariate longitudinal panel cost-related analysis controlling for treatment, patient characteristics, risk group, annual time dummies, bladder cancer events, and interactions.